Fetal Growth Restriction
Cross-source consensus on Fetal Growth Restriction from 1 sources and 4 claims.
1 sources · 4 claims
How it works
Dosage & preparation
Risks & contraindications
Other
Highlighted claims
- Fetal growth restriction most often arises from placental insufficiency and is a major independent risk factor for stillbirth and serious adverse perinatal outcomes. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
- FGR and pre-eclampsia share poor placental function from reduced placental perfusion as a common pathophysiological root. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
- The trial defines FGR as estimated fetal weight below the third centile on fetal growth charts, classified by a recent Delphi consensus. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial
- Normotensive FGR patients in cohort 2.3 require a lower DM199 dose intended to vasodilate uteroplacental vessels without causing maternal hypotension. — Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I/II open-label trial